Clinical Trials Results - National Cancer Institute

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/23/2007 First Published: 11/24/2002


1.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				ERLANGEN-1490 EU-20232, NCT00053391

Last Modified: 6/27/2006 First Published: 8/1/2000


2.		Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				LAC-USC-10M991 NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

Last Modified: 11/1/1999 First Published: 10/1/1998


3.		Phase I Study of CD40-Ligand (CD154) Gene-Transduced Leukemia Cells in Patients with Chronic Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				Over 21				NCI				UCSD-970976 NCI-G98-1477

Last Modified: 4/1/2002 First Published: 5/1/2001


4.		Phase I Study of CD40-Ligand and Flt3 Ligand in Patients With Metastatic Melanoma or Renal Cell Cancer (Summary Last Modified 04/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				16 and over				NCI				NCI-01-C-0121 NCI-1035, NCT00020540, 1035


5.		Treating High Risk Leukemia With CD40 Ligand & IL-2 Gene Modified Tumor Vaccine.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				75 and under				Other				H6408 NCT00058799

Select All on One Page